Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to gather information to develop a heart failure screening and prevention program.
All participants will undergo phlebotomy for specimen collection (BNP, hs-cTn, BMP and lipid testing, biorepository storage) and baseline echocardiography. All participants will additionally be administered a health and lifestyle questionnaire, undergo measurement of vital signs, and receive uniform education on heart-healthy lifestyle and signs and symptoms of heart failure. Participants who are randomized to the intervention arm will receive a referral to Heart Failure Prevention Clinic, a pharmacist-directed practice in collaboration with an attending cardiologist, where they will be followed for 1 year, with their primary care physician updated after each visit. The information from their BNP, hs-cTn, and echocardiography will be provided to them and their primary care physicians as well as the pharmacist and cardiologist team members. The participants (and their primary care providers) who are randomized to usual care will be blinded to their BNP and hs-cTn values and echocardiography results.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pharmacist-directed collaborative practice | Experimental | Participants will be referred to a pharmacist-directed collaborative practice for heart failure prevention. |
|
| Usual care | No Intervention | Participants will receive usual care with their primary care physician. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Heart Failure Prevention Clinic | Other | Heart Failure Prevention Clinic is a pharmacist-directed practice in collaboration with an attending cardiologist that uses evidence-based guidelines to optimize medications and lifestyle interventions for heart failure prevention. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in BNP at 1 year | All participants will have brain natriuretic peptide (BNP) measured at baseline and at 1-year follow-up. | baseline, 1-year |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in hs-cTn at 1 year | All participants will have high sensitivity cardiac troponin (hs-cTn) measured at baseline and at 1-year follow-up. | baseline, 1-year |
| Change from baseline in BP at 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Medication adherence at 1 year | All participants will be asked about adherence to medications (if applicable) using questions of nonadherence from the Atherosclerosis Risk in Communities study. | 1 year |
| Change from baseline in E/e' ratio at 1 year |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sadiya Khan, MD, MSc | Northwestern University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Northwestern University Department of Preventive Medicine | Chicago | Illinois | 60611 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40664007 | Derived | Wang MC, Dolan B, Huang X, Freaney PM, Freed BH, Vega L, Markoski N, Wainright A, Kane B, Seegmiller LE, Shah SJ, Yancy CW, Neeland IJ, Ning H, Lloyd-Jones DM, Khan SS. Feasibility of the Implementation of Tools for Heart Failure Risk Prediction: A Randomized Controlled Pilot Trial. JACC Adv. 2025 Aug;4(8):102004. doi: 10.1016/j.jacadv.2025.102004. Epub 2025 Jul 14. | |
| 34912869 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
All participants will have systolic blood pressure and diastolic blood pressure measured at baseline and at 1-year follow-up.
| baseline, 1-year |
| Change from baseline in weight status at 1 year | All participants will have weight and BMI measured at baseline and at 1-year follow-up. | baseline, 1-year |
| Change from baseline in serum glucose at 1 year | All participants will have serum glucose measured at baseline and at 1-year follow-up. | baseline, 1-year |
| Change from baseline in LDL at 1 year | All participants will have LDL cholesterol measured at baseline and at 1-year follow-up. | baseline, 1-year |
| Change from baseline in estimated glomerular filtration rate at 1 year | All participants will have estimated glomerular filtration rate measured at baseline and at 1-year follow-up. | baseline, 1-year |
| Change from baseline in creatinine at 1 year | All participants will have creatinine measured at baseline and at 1-year follow-up. | baseline, 1-year |
| Smoking quit attempt or cessation | All participants will be asked about smoking status at baseline and at 1-year follow-up. Outcome is, among patients who were current smokers at baseline, quit attempt or no smoking at 1 year. | baseline, 1-year |
All participants will undergo echocardiogram at baseline and at 1 year.
| baseline, 1-year |
| Change from baseline in left ventricular mass index at 1 year | All participants will undergo echocardiogram at baseline and at 1 year. | baseline, 1-year |
| Biomarker assay | All participants will have biorepository storage of serum and plasma at baseline. An exploratory analysis will use a commercial biomarker array to investigate correlations with echocardiogram, BNP, and hs-cTn results. | baseline |
| Change from baseline in fruit and vegetable intake | All participants will be asked about fruit and vegetable intake at baseline and at 1 year. Outcome will be measured in servings/week. | baseline, 1-year |
| Change from baseline in salt intake | All participants will be asked about salt intake at baseline and at 1 year using a 5-point Likert scale (always, often, sometimes, rarely, never). A higher score on this scale is preferable. | baseline, 1-year |
| Change from baseline in physical activity | All participants will be asked about physical activity at baseline and at 1 year. Outcome is measured in minutes of moderate-intensity activity per week. Vigorous-intensity activity will count as twice the equivalent duration of moderate-intensity activity. | baseline, 1-year |
| Change from baseline in sedentary behavior | All participants will be asked about sedentary behavior at baseline and at 1 year. Outcome is measured in minutes of sedentary behavior per day. | baseline, 1-year |
| Change from baseline in health utility | Health utility will be measured by the EurolQol 5 Dimensions 5 Levels (EQ-5D-5L) instrument. Typical scores range from 0 to 1, with 1 being ideal health-related quality of life. | baseline, 1-year |
| Change from baseline in overall health | Overall health will be measured by the EurolQol Visual Analog Scale (EQ VAS) instrument. Scores range from 0-100, with 100 being the highest overall health. | baseline, 1-year |
| Wang MC, Dolan B, Freed BH, Vega L, Markoski N, Wainright AE, Kane B, Seegmiller LE, Harrington K, Lewis AA, Shah SJ, Yancy CW, Neeland IJ, Ning H, Lloyd-Jones DM, Khan SS. Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study. Front Cardiovasc Med. 2021 Nov 29;8:785109. doi: 10.3389/fcvm.2021.785109. eCollection 2021. |